본문 바로가기
KERD
논문KCI 등재

Comprehensive Clinical Study of Concurrent Chemotherapy Breathing IMRT Middle Part of Locally Advanced Esophageal Cancer

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

주제분류방사선과학

초록

The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation ther-apy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated in-tensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radio-therapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in pa-tients with locally advanced mid-esophageal cancer (AEC).

Abstract

The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation ther-apy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated in-tensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radio-therapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in pa-tients with locally advanced mid-esophageal cancer (AEC).

참고문헌 (35)

  1. Ulmer W, "3D photon superposition", convolution algorithm and its foundation on results of Monte Carlo calculations, 2005, pp.50(8), 1767~1790
  2. Geh JI, "Systematic overview of preoperative (neoadjuvant)chemo-radiotherapy trials in oesophageal cancer:evidence of a radiation and chemotherapy dose response", Radiother Oncol, 78(3), pp.236~234 (2006)
  3. Webb S, "A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density", Phys Med Biol, 38(6), pp.653~666 (1993)
  4. Gagliardi G, "Radiation dose-volume effects in the heart", Int J Radiat Oncol Biol Phys, 76, pp.S77~S85 (2010)
  5. Lyman JT, "Complication probability as assessed from dose-volume histograms", Radiat Res Suppl, 8, pp.S13~S19 (1985)
  6. Kutcher GJ, "Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method", Int J Radiat Oncol Biol Phys, 16(6), pp.1623~1630 (1989)
  7. Keall PJ, "The management of respiratory motion in radiation oncology report of AAPM Task Group 76", Med Phys, 33(10), pp.3874~3900 (2006)
  8. Cohen RJ, "Esophageal motion during radiotherapy: quantification and margin implications", Dis Esophagus, 23(6), pp.473~479 (2010)
  9. Gao XS, "Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma", Int J Radiat Oncol Biol Phys, 67(2), pp.389~396 (2007)
  10. Welsh J, "Esophageal cancer dose escalation using a simultaneous integrated boost technique", Int J Radiat Oncol Biol Phys, 82(1), pp.468~474 (2012)
  11. Prescribing, recording and reporting photon beam therapy, "International Commission on Radiation Units and Measurements", ICRU, ~, pp.ICRU report 62
  12. Keal P, "The clinical implementation of respiratory-gated intensity-modulated radiotherapy", Med Dosim, 31(2), pp.152~162 (2006)
  13. Wallis JW, "Three-dimensional display in nuclear medicine", Med Imag IEEE Trans, 8(2), pp.297~330 (1989)
  14. Wolf MC, "Curative treatment of esophageal carcinoma: Current options and future developments", Radiat Oncol, 6(1), pp.55~ (2011)
  15. Teoh AY, "Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial", Ann Oncol, 24(1), pp.165~171 (2012)
  16. Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 362(9), pp.858~859 (2010)
  17. Button MR, "Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy", Int J Radiat Oncol Biol Phys, 73(3), pp.818~823 (2009)
  18. Zhang Z, "Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy", Int J Radiat Oncol Biol Phys, 61(3), pp.656~664 (2005)
  19. Geh JI, "Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer:Evidence of a radiation and chemotherapy dose response", Radiother Oncol, 78(3), pp.236~244 (2005)
  20. Minsky BD, "INT 0123(Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy", J Clin Oncol, 20(5), pp.1167~1174 (2002)
  21. Gwynne S, "Oesophageal chemoradiotherapy in the UK: current practice and future directions", Clin Oncol (R Coll Radiol), 25(6), pp.368~377 (2013)
  22. Martel MK, "Fraction size and dose parameters related to the incidence of pericardial effusions", Int J Radiat Oncol Biol Phys, 40(1), pp.155~161 (1998)
  23. Hatakenaka M, "Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: Magnetic resonance evaluation", Int J Radiat Oncol Biol Phys, 83(1), pp.e67~e73 (2012)
  24. Bedenne L, "Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102", J Clin Oncol, 25(10), pp.1160~1168 (2007)
  25. Ishida K, "Phase II study of cisplatin and 5 fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)", Japan Clinical Oncology Group trial (JCOG9516), 2004, pp.34(10), 615~619
  26. Ilson DH, "Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus", J Clin Oncol, 16(5), pp.1826~1834 (1998)
  27. Dunne AL, "Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action", Oncol Res, 14(9), pp.447~454 (2004)
  28. Higuchi K, "A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501)", Radiother Oncol, 87(3), pp.398~404 (2008)
  29. Donahue JM, "Complete pathologic response after neoadjuvant chemo-radiotherapy for esophageal cancer is associated with enhanced survival", Ann Thorac Surg, 87(2), pp.398~398 (2009)
  30. Siegel R, "Cancer statistics 2012", Cancer J Clin, 62(1), pp.10~29 (2012)
  31. Orringer MB, "Transhiatal esophagectomy: clinical experience and refinements", Ann Surg, 230(3), pp.392~400 (1999)
  32. Chang AC, "Outcomes after transhiatal and transthoracic esophagectomy for cancer", Ann Thorac Surg, 85(2), pp.424~429 (2008)
  33. Suzuki A, "Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemo-radiotherapy", Cancer, 117(21), pp.4823~4833 (2011)
  34. Gillies RS, "Role of positron emission tomography–computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma", Br J Surg, 99(2), pp.239~245 (2012)
  35. Prins MJ, "The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study", Ann Oncol, 24(5), pp.1290~1297 (2013)

관련 논문AI추천

Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy김대은, 김미영, 김민지, 김승헌, 김의진, 나국주, 남택근, 배우균, 심현정, 정익주, 조상희, 최원영, 황준을대한암학회 · Cancer Research and Treatment2013 · 제45권 제4호Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy김현주, 서양권, 신성관, 이상길, 이용찬, 이창걸, 조병철대한암학회 · Cancer Research and Treatment2017 · 제49권 제3호Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer PatientsHyun Seok Lee, Sang Jik Lee, Seong Woo Jeon, Sung Kook Kim, Su Youn Nam, Yong Hwan Kwon거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제4호Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal CancerEui Sil Hong, Il Young You, Ji Young Chai, Joung Muk Leem, Ki Hyeong Lee, Min Ok Kim, Seung Taik Kim, Won Dong Kim, Woo Yoon Park대한암학회 · Cancer Research and Treatment2003 · 제35권 제4호Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective김경환, 김대준, 박경란, 이익재, 이창걸, 장지석, 조병철, 차지혜대한암학회 · Cancer Research and Treatment2017 · 제49권 제1호Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and ToxicitiesBin Wang, Bo Qiu, Hui Liu, Jin-Yu Guo, Jun Zhang, Ling-Zhi Cai, Meng-Yun Qiang, Meng-Zhong Liu, Nai-Bin Chen, Qi-Wen Li, Qun Li, Shao-Min Huang, Yong-Hong Hu, Yu-Jia Zhu대한암학회 · Cancer Research and Treatment2020 · 제52권 제1호

이 간행물의 다른 논문 (18건)